WEBULL

ASX Penny Stocks: EMVision Medical Devices Leads Our Trio Of Picks

Simply Wall St · 06/13/2025 02:05

As Australian shares are set to advance slightly, buoyed by positive U.S. inflation data and a stable commodities market, investors are keenly observing the opportunities within the local stock landscape. Despite its vintage feel, the term 'penny stocks' continues to hold relevance for those interested in smaller or newer companies that offer both affordability and growth potential. In this article, we explore three penny stocks that stand out for their financial strength and potential for long-term value creation.

Top 10 Penny Stocks In Australia

Name Share Price Market Cap Rewards & Risks
EZZ Life Science Holdings (ASX:EZZ) A$1.735 A$81.85M ✅ 4 ⚠️ 2 View Analysis >
GTN (ASX:GTN) A$0.605 A$115.47M ✅ 3 ⚠️ 2 View Analysis >
IVE Group (ASX:IGL) A$2.76 A$425.54M ✅ 4 ⚠️ 2 View Analysis >
Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ✅ 5 ⚠️ 1 View Analysis >
Tasmea (ASX:TEA) A$3.10 A$730.43M ✅ 3 ⚠️ 2 View Analysis >
Regal Partners (ASX:RPL) A$2.22 A$746.28M ✅ 4 ⚠️ 3 View Analysis >
Accent Group (ASX:AX1) A$1.805 A$1.09B ✅ 4 ⚠️ 2 View Analysis >
Lindsay Australia (ASX:LAU) A$0.705 A$223.61M ✅ 4 ⚠️ 2 View Analysis >
Bisalloy Steel Group (ASX:BIS) A$3.27 A$155.16M ✅ 3 ⚠️ 1 View Analysis >
CTI Logistics (ASX:CLX) A$1.79 A$144.17M ✅ 4 ⚠️ 2 View Analysis >

Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

EMVision Medical Devices (ASX:EMV)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, along with other medical imaging needs in Australia, with a market cap of A$156.92 million.

Operations: The company generates revenue primarily from the research and development of medical device technology, amounting to A$8.06 million.

Market Cap: A$156.92M

EMVision Medical Devices Ltd, with a market cap of A$156.92 million, remains pre-revenue as it focuses on developing its neurodiagnostic technology. The company has more cash than debt and maintains a stable cash runway exceeding one year. Recent developments include the commencement of a pivotal trial for its emu™ Brain Scanner, aimed at stroke diagnosis and potentially supporting FDA clearance. This trial could pave the way for future product expansions in the medical imaging field. EMVision's board recently welcomed Carmel Monaghan as an Independent Non-Executive Director, bringing extensive healthcare experience to support strategic growth initiatives.

ASX:EMV Financial Position Analysis as at Jun 2025
ASX:EMV Financial Position Analysis as at Jun 2025

LGI (ASX:LGI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: LGI Limited focuses on carbon abatement and renewable energy solutions using biogas from landfill, with a market cap of A$267.31 million.

Operations: The company generates revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million).

Market Cap: A$267.31M

LGI Limited, with a market cap of A$267.31 million, is generating revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Despite the company's earnings contracting by 15.3% over the past year, its debt management remains strong with operating cash flow covering 34.4% of its debt and a reduced debt-to-equity ratio from 146.5% to 46.2% over five years. While LGI's net profit margin has decreased to 17.4%, it maintains stable weekly volatility at 4%. The board is experienced, though management tenure averages only 1.3 years.

ASX:LGI Revenue & Expenses Breakdown as at Jun 2025
ASX:LGI Revenue & Expenses Breakdown as at Jun 2025

NRW Holdings (ASX:NWH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: NRW Holdings Limited, with a market cap of A$1.36 billion, offers diversified contract services to the resources and infrastructure sectors in Australia through its subsidiaries.

Operations: NRW Holdings generates revenue from three main segments: Mining at A$1.56 billion, MET at A$853.22 million, and Civil at A$776.06 million.

Market Cap: A$1.36B

NRW Holdings, with a market cap of A$1.36 billion, demonstrates strong financial health through well-covered interest payments and operating cash flow that exceeds its debt by a large margin. The company's earnings have grown significantly by 29.9% over the past year, surpassing both its historical average and industry growth rates. Despite having low return on equity at 17.3%, NRW is trading below estimated fair value and has not diluted shareholders recently. Short-term assets exceed liabilities, indicating robust liquidity management, while recent executive changes bring seasoned leadership to the finance team with Peter Bryant as CFO starting in May 2025.

ASX:NWH Revenue & Expenses Breakdown as at Jun 2025
ASX:NWH Revenue & Expenses Breakdown as at Jun 2025

Taking Advantage

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.